Trials / Completed
CompletedNCT01105832
Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?
Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer?
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University Hospital, Linkoeping · Academic / Other
- Sex
- Female
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
40 postmenopausal women, with a non-operated proximal humeral fracture, will be randomized to standard treatment (physiotherapy) or standard treatment + Forsteo (rhPTH 1-34) during 4 weeks. Follow-up will be at 7 weeks and 3 months including x-ray and DASH score (The Disabilities of the Arm, Shoulder and Hand) measuring physical function, and pain on a visual analoge scale (VAS). Two doctors, blinded to the treatment, will judge the callus formation and healing on the x-rays and guess the treatment. The DASH score and the pain score will be compared between the treatment groups. The investigators hypotheses are that callus formation and healing will be more pronounced and that patients have less pain and better function in the rhPTH 1-34 group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teriparatide | Teriparatide (Forsteo) 20 micrograms daily during four weeks |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2014-02-01
- Completion
- 2014-09-01
- First posted
- 2010-04-19
- Last updated
- 2014-12-10
Locations
2 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT01105832. Inclusion in this directory is not an endorsement.